AG0034RV

363-24-6 | Prostaglandin E2 MaxSpec® Standard

AG0034RV

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	363-24-6
Catalog Number	AG0034RV(AGN-PC-0RC30N)
Chemical Name	Prostaglandin E2 MaxSpec® Standard
EC Number	206-656-6
IUPAC Name	(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
InChI	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
InChI Key	XEYBRNLFEZDVAW-ARSRFYASSA-N
MDL Number	MFCD00077861
Molecular Formula	C20H32O5
Molecular Weight	352.4651
SMILES	CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)CC=C/CCCC(O)=O
UNII	K7Q1JQR04M
Synonyms	alpha, PGE2, alpha, Prostaglandin E2, Dinoprostone, E2 alpha, Prostaglandin, E2, Prostaglandin, E2alpha, Prostaglandin, Gel, Prepidil, PGE2, PGE2 alpha, PGE2alpha, Prepidil Gel, Prostaglandin E2, Prostaglandin E2 alpha, Prostaglandin E2alpha, Prostenon, Prostaglandin E2, Dinoprostone, PGE2, 363-24-6, Prostin E2, Prepidil, Cervidil, Propess, Minprositin E2, Minprostin E2, Dinoproston, Prostin, Prostarmon E, Dinoprostonum, (15S)-Prostaglandin E2, l-Prostaglandin E2, Dinoprostona, PGE2alpha, l-PGE2, Prostaglandin E2alpha, Dinoprostonum [INN-Latin], Dinoprostona [INN-Spanish], U-12062, Prostaglandin E, (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, UNII-K7Q1JQR04M, NSC 165560, [3H]PGE2, (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid, U 12062, [3H]prostaglandin E2, (-)-Prostaglandin E2, EINECS 206-656-6, CHEMBL548, NSC 196514, K7Q1JQR04M, l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid, CHEBI:15551, XEYBRNLFEZDVAW-ARSRFYASSA-N, (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-, Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-, MFCD00077861, Prostaglandin E(2), (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid, (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid, NCGC00092361-05, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate, Prostaglandin E2.alpha., (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate, Prepidil Gel, (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, DSSTox_CID_2947, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, DSSTox_RID_76801, DSSTox_GSID_22947, 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid, PGE2 alpha, (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid, 9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid, Cerviprime, Prostaglandin E2 alpha, Prostenone, Enzaprost E, Prostin E, Prostarmon E2, Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-, Cervidil (TN), Prepidil (TN), CAS-363-24-6, Prostaglandin,PGE2, U,062, Prostin E2 (TN), SR-05000001459, Dinoprostone [USAN:INN:BAN:JAN], Dinoprostone Prostaglandin E2, Dinoprostone (JAN/USP/INN), (5Z,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, BML1-F07, Prosta-5, (5Z,11.alpha.,13E,15S)-11,15-dihydroxy-9-oxo-, Prosta-5, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, Prosta-5, 11,5-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid, [3H]dinoprostone, 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, prosta-glandin e2, NCGC00092361-06, (E,2R,3R)-7-[3-hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid, P2E, Prestwick_793, [3H]prostin E2, BMS-279654 & PGE2, Dinoprostone beta-Cyclodextrin Clathrate, AC1NQWXW, Dinoprostone [USAN:USP:INN:BAN:JAN], prostaglandin-e2-cervidil, Prostaglandin E2, 98%, (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic, Prostaglandin E2 (PGE2), SCHEMBL25533, BSPBio_001490, GTPL1883, GTPL1916, (5Z,11|A,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, DTXSID4022947, [3H]-PGE2, BDBM35847, HMS1361K12, HMS1791K12, HMS1989K12, HMS2089D17, HMS3268J12, HMS3402K12, HMS3648F07, HMS3677C20, EX-A1773, ZINC3830713, Tox21_111196, LMFA03010003, NSC165560, NSC196514, (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, AKOS015920228, Tox21_111196_1, AC-6098, CCG-208092, CCG-208256, CS-6932, DB00917, NSC-165560, NSC-196514, RP17686, IDI1_033960, SMP2_000056, NCGC00092361-01, NCGC00092361-02, NCGC00092361-03, NCGC00092361-04, AJ-45765, AN-10387, BC219642, BR-72815, PGE2-[3,3,4,4-d4], HY-101952, LS-125823, B7005, P1884, 1798-EP2272832A1, 1798-EP2277848A1, 1798-EP2277858A1, 1798-EP2295055A2, 1798-EP2298767A1, 1798-EP2301922A1, 1798-EP2305641A1, 1798-EP2305653A1, 1798-EP2308510A1, 1798-EP2308872A1, 1798-EP2311453A1, 1798-EP2311808A1, 1798-EP2311829A1, 1798-EP2314574A1, 1798-EP2314587A1, 1798-EP2316829A1, C00584, D00079, Prostaglandin E2, >=93% (HPLC), synthetic, 363P246, SR-01000946417, J-502620, SR-01000946417-1, SR-05000001459-1, SR-05000001459-3, SR-05000001459-4, U-12,062, BRD-K26521938-001-04-9, 05D31BD5-818B-4A92-8CFC-BEC19926A5B3, Dinoprostone, European Pharmacopoeia (EP) Reference Standard, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid, (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoate, Dinoprostone, United States Pharmacopeia (USP) Reference Standard, (5Z,11?,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1oic acid, (5Z,11I+/-,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoic acid, Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture, (5Z,11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI), Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, Prostaglandin E2, gamma-irradiated, powder, BioXtra, suitable for cell culture, Cerviprost, Glandin, Prostenon, primiprost, Gel, Prepidil, E2, Prostaglandin, alpha, PGE2, Propess (TN), E2alpha, Prostaglandin, 5-trans-PGE2, alpha, Prostaglandin E2, E2 alpha, Prostaglandin, VIVELLE-DOT, 8-isoprostaglandin E2, D06FEA, C20H32O5, FA(20:2(OH2,Ke,cyclo)), Dinoprostone [USAN:BAN:INN:JAN], C20-H32-O5, CID5280360, CS-O-01407, Prostaglandin E2, 98% - 10MG 10mg, D015232, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI), Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11?,13E,15S)-,

Complexity	469
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	4
Defined Bond Stereocenter Count	2
Exact Mass	352.225g/mol
Formal Charge	0
Heavy Atom Count	25
Hydrogen Bond Acceptor Count	5
Hydrogen Bond Donor Count	3
Isotope Atom Count	0
Molecular Weight	352.471g/mol
Monoisotopic Mass	352.225g/mol
Rotatable Bond Count	12
Topological Polar Surface Area	94.8A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	2.8

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number